The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments

키워드

참고문헌 (176)

1. Viale PH, "The American Cancer Society's Facts & Figures : 2020 Edition", J. Adv. Pract. Oncol, 11, pp.135~136 (2020)
2. Rebecca L. Siegel, "Cancer statistics, 2019", CA: A Cancer Journal for Clinicians, 69(1), pp.7~34 (2019), Wiley[DOI]
3. Islami F, "Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States", CA Cancer J. Clin, 68, pp.31~54 (2018)
4. Bouvard V, "A review of human carcinogens--Part B : biological agents", Lancet Oncol, 10, pp.321~322 (2009)
5. Dass S. Vinay, "Immune evasion in cancer: Mechanistic basis and therapeutic strategies", Seminars in Cancer Biology, 35, pp.S185~S198 (2015), Elsevier BV[DOI]
6. Togashi Y, "Regulatory T cells in cancer immunosuppression-implications for anticancer therapy", Nat. Rev. Clin. Oncol, 16, pp.356~371 (2019)
7. Tanaka A, "Regulatory T cells in cancer immunotherapy", Cell Res, 27, pp.109~118 (2017)
8. Itahashi K, "Regulatory T-cell development in the tumor microenvironment", Eur. J. Immunol, 52, pp.1216~1227 (2022)
9. Chen BJ, "Immunotherapy of cancer by targeting regulatory T cells", Int. Immunopharmacol, 104, pp.108469~ (2022)
10. Fan Y, "Gut microbiota in human metabolic health and disease", Nat. Rev. Microbiol, 19, pp.55~71 (2021)
11. Sorbara MT, "Microbiome-based therapeutics", Nat. Rev. Microbiol, 20, pp.365~380 (2022)
12. Gilbert JA, "Current understanding of the human microbiome", Nat. Med, 24, pp.392~400 (2018)
13. Hooper LV, "Interactions between the microbiota and the immune system", Science, 336, pp.1268~1273 (2012)
14. Zheng D, "Interaction between microbiota and immunity in health and disease", Cell Res, 30, pp.492~506 (2020)
15. Lazar V, "Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer", Front. Immunol, 9, pp.1830~ (2018)
16. Marchesi JR, "The vocabulary of microbiome research : a proposal", Microbiome, 3, pp.31~ (2015)
17. Berg G, "Microbiome definition re-visited : old concepts and new challenges", Microbiome, 8, pp.103~ (2020)
18. Cho I, "The human microbiome : at the interface of health and disease", Nat. Rev. Genet, 13, pp.260~270 (2012)
19. Hubert E. Blum, "The human microbiome", Advances in Medical Sciences, 62(2), pp.414~420 (2017), Elsevier BV[DOI]
20. Malla MA, "Exploring the human microbiome : the potential future role of next-generation sequencing in disease diagnosis and treatment", Front. Immunol, 9, pp.2868~ (2018)
21. Wensel CR, "Next-generation sequencing : insights to advance clinical investigations of the microbiome", J. Clin. Invest, 132, pp.e154944~ (2022)
22. Finotello F, "Measuring the diversity of the human microbiota with targeted next-generation sequencing", Brief Bioinform, 19, pp.679~692 (2018)
23. Browne HP, "Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation", Nature, 533, pp.543~546 (2016)
24. Backhed F, "Host-bacterial mutualism in the human intestine", Science, 307, pp.1915~1920 (2005)
25. Gill SR, "Metagenomic analysis of the human distal gut microbiome", Science, 312, pp.1355~1359 (2006)
26. Sender R, "Revised estimates for the number of human and bacteria cells in the body", PLoS Biol, 14, pp.e1002533~ (2016)
27. Morais LH, "The gut microbiota-brain axis in behaviour and brain disorders", Nat. Rev. Microbiol, 19, pp.241~255 (2021)
28. Tripathi A, "The gut-liver axis and the intersection with the microbiome", Nat. Rev. Gastroenterol. Hepatol, 15, pp.397~411 (2018)
29. Budden KF, "Emerging pathogenic links between microbiota and the gut-lung axis", Nat. Rev. Microbiol, 15, pp.55~63 (2017)
30. O'Mahony SM, "Serotonin, tryptophan metabolism and the brain-gut-microbiome axis", Behav. Brain Res, 277, pp.32~48 (2015)
31. Yu G, "Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features", Genome Biol, 17, pp.163~ (2016)
32. Rizzo AE, "The female reproductive tract microbiome-implications for gynecologic cancers and personalized medicine", J. Pers. Med, 11, pp.546~ (2021)
33. Ravel J, "Vaginal microbiome of reproductive-age wome", Proc. Natl. Acad. Sci. USA, 108(1), pp.4680~4687 (2011)
34. Eslami S, "Lactobacillus crispatus strain SJ-3C-US induces human dendritic cells(DCs)maturation and confers an anti-inflammatory phenotype to DCs", APMIS, 124, pp.697~710 (2016)
35. Jain T, "New insights into the cancer-microbiome-immune axis : decrypting a decade of discoveries", Front. Immunol, 12, pp.622064~ (2021)
36. Sepich-Poore GD, "The microbiome and human cancer", Science, 371, pp.eabc4552~ (2021)
37. Helmink BA, "The microbiome, cancer, and cancer therapy", Nat. Med, 25, pp.377~388 (2019)
38. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 68, pp.394~424 (2018)
39. Qin J, "A human gut microbial gene catalogue established by metagenomic sequencing", Nature, 464, pp.59~65 (2010)
40. Turnbaugh PJ, "An obesity-associated gut microbiome with increased capacity for energy harvest", Nature, 444, pp.1027~1031 (2006)
41. Chung H, "Gut immune maturation depends on colonization with a host-specific microbiota", Cell, 149, pp.1578~1593 (2012)
42. Maruvada P, "The human microbiome and obesity : moving beyond associations", Cell Host Microbe, 22, pp.589~599 (2017)
43. Reddy BS, "Colon carcinogenesis in germ-free rats with 1, 2-dimethylhydrazine and N-methyl-n'-nitro-N-nitrosoguanidine", Cancer Res, 34, pp.2368~2372 (1974)
44. Reddy BS, "Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats", Cancer Res, 35, pp.287~290 (1975)
45. Onoue M, "Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1, 2-dimethylhydrazine in rats", Cancer Lett, 113, pp.179~186 (1997)
46. Sears CL, "Bacteroides fragilis subverts mucosal biology : from symbiont to colon carcinogenesis", J. Clin. Invest, 124, pp.4166~4172 (2014)
47. Swidsinski A, "Association between intraepithelial Escherichia coli and colorectal cancer", Gastroenterology, 115, pp.281~286 (1998)
48. Ramirez-Labrada AG, "The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy", Trends Cancer, 6, pp.86~97 (2020)
49. Liu NN, "Microbiome dysbiosis in lung cancer : from composition to therapy", NPJ Precis Oncol, 4, pp.33~ (2020)
50. Liu HX, "Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects", Int. J. Cancer, 142, pp.769~778 (2018)
51. Liu Y, "Lung tissue microbial profile in lung cancer is distinct from emphysema", Am. J. Cancer Res, 8, pp.1775~1787 (2018)
52. Cameron SJS, "A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer", PLoS One, 12, pp.e0177062~ (2017)
53. Yan X, "Discovery and validation of potential bacterial biomarkers for lung cancer", Am. J. Cancer Res, 5, pp.3111~3122 (2015)
54. Lee SH, "Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions", Lung Cancer, 102, pp.89~95 (2016)
55. Sims TT, "Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation", Commun. Biol, 4, pp.237~ (2021)
56. Riquelme E, "Tumor microbiome diversity and composition influence pancreatic cancer outcomes", Cell, 178, pp.795~806 (2019)
57. Chao XP, "Correlation between the diversity of vaginal microbiota and the risk of high-risk human papillomavirus infection", Int. J. Gynecol. Cancer, 29, pp.28~34 (2019)
58. Keller MJ, "Impact of Herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome", J. Infect. Dis, 220, pp.852~861 (2019)
59. Liu CM, "The effect of antiretroviral therapy initiation on the vaginal microbiome in HIV-infected women", Open Forum Infect. Dis, 6, pp.ofz328~ (2019)
60. Jiang N, "The effect of TLR4 on the growth and local inflammatory microenvironment of HPVrelated cervical cancer in vivo", Infect. Agent Cancer, 15, pp.12~ (2020)
61. Chao X, "Research of the potential biomarkers in vaginal microbiome for persistent high-risk human papillomavirus infection", Ann. Transl. Med, 8, pp.100~ (2020)
62. Blanco R, "Human Papillomavirus in breast carcinogenesis : A passenger, a cofactor, or a causal agent?", Biology(Basel), 10, pp.804~ (2021)
63. Sher G, "Prevalence and type distribution of high-risk human papillomavirus(HPV)in breast cancer : A qatar based study", Cancers(Basel), 12, pp.1528~ (2020)
64. Di Lonardo A, "Human papillomavirus in breast cancer", Breast Cancer Res. Treat, 21, pp.95~100 (1992)
65. Kan CY, "Identification of human papillomavirus DNA gene sequences in human breast cancer", Br. J. Cancer, 93, pp.946~948 (2005)
66. Heng B, "Human papilloma virus is associated with breast cancer", Br. J. Cancer, 101, pp.1345~1350 (2009)
67. Nejman D, "The human tumor microbiome is composed of tumor typespecific intracellular bacteria", Science, 368, pp.973~980 (2020)
68. Thompson KJ, "A comprehensive analysis of breast cancer microbiota and host gene expression", PLoS One, 12, pp.e0188873~ (2017)
69. Olszak T, "Microbial exposure during early life has persistent effects on natural killer T cell function", Science, 336, pp.489~493 (2012)
70. Zhang D, "Neutrophil ageing is regulated by the microbiome", Nature, 525, pp.528~532 (2015)
71. Paulos CM, "Microbial translocation augments the function of adoptively transferred self", tumor-specific CD8+ T cells via TLR4 signaling, 2007, pp.117, 2197~2204
72. Uribe-Herranz M, "Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response", J. Clin. Invest, 130, pp.466~479 (2020)
73. Schaupp L, "Microbiota-induced type I interferons instruct a poised basal state of dendritic cells", Cell, 181, pp.1080~1096 (2020)
74. Nair S, "Natural killer T cells in cancer immunotherapy", Front. Immunol, 8, pp.1178~ (2017)
75. Ma C, "Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells", Science, 360, pp.eaan5931~ (2018)
76. Shen S, "Invariant natural killer T cells shape the gut microbiota and regulate neutrophil recruitment and function during intestinal inflammation", Front. Immunol, 9, pp.999~ (2018)
77. Saqib U, "Phytochemicals as modulators of M1-M2 macrophages in inflammation", Oncotarget, 9, pp.17937~17950 (2018)
78. Mills CD, "M1 and M2 macrophages : Oracles of health and disease", Crit. Rev. Immunol, 32, pp.463~488 (2012)
79. Xue J, "Transcriptome-based network analysis reveals a spectrum model of human macrophage activation", Immunity, 40, pp.274~288 (2014)
80. Van den Bossche J, "Metabolic regulation of macrophages in tissues", Cell Immunol, 330, pp.54~59 (2018)
81. Pathria P, "Targeting tumor-associated macrophages in cancer", Trends Immunol, 40, pp.310~327 (2019)
82. Pushalkar S, "The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression", Cancer Discov, 8, pp.403~416 (2018)
83. Kostic AD, "Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment", Cell Host Microbe, 14, pp.207~215 (2013)
84. Park HE, "Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma", Virchows Arch, 471, pp.329~336 (2017)
85. Yang Y, "Focused specificity of intestinal TH17 cells towards commensal bacterial antigens", Nature, 510, pp.152~156 (2014)
86. Sun M, "Microbiota-derived short-chain fatty acids promote Th1 cell IL-10production to maintain intestinal homeostasis", Nat. Commun, 9, pp.3555~ (2018)
87. Atarashi K, "Induction of colonic regulatory T cells by indigenous Clostridium species", Science, 331, pp.337~341 (2011)
88. Geuking MB, "Intestinal bacterial colonization induces mutualistic regulatory T cell responses", Immunity, 34, pp.794~806 (2011)
89. 이나은, "Microbiota in T-cell homeostasis and inflammatory diseases", Experimental and Molecular Medicine, 49, pp.1~10 (2017), 생화학분자생물학회
90. Salvador R, "Microbiota as drivers and as therapeutic targets in ocular and tissue specific autoimmunity", Front. Cell Dev. Biol, 8, pp.606751~ (2020)
91. Abdel-Gadir A, "Microbiota therapy acts via a regulatory T cell MyD88", RORgammat pathway to suppress food allergy, 2019, pp.25, 1164~1174
92. Sethi V, "Gut Microbiota promotes tumor growth in mice by modulating immune response", Gastroenterology, 155, pp.33~37 (2018)[DOI]
93. Burnet FM, "The concept of immunological surveillance", Prog. Exp. Tumor Res, 13, pp.1~27 (1970)
94. Josrgen Rygaard, "The Nude Mouse vs. The Hypothesis of Immunological Surveillance", Immunological Reviews, 28(1), pp.43~61 (1976), Wiley[DOI]
95. Dunn GP, "Interferons, immunity and cancer immunoediting", Nat. Rev. Immunol, 6, pp.836~848 (2006)
96. Shankaran V, "IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity", Nature, 410, pp.1107~1111 (2001)
97. Tauriello DVF, "Overcoming TGFbeta-mediated immune evasion in cancer", Nat. Rev. Cancer, 22, pp.25~44 (2022)
98. Kim SK, "The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment", Front. Pharmacol, 13, pp.868695~ (2022)
99. Bogen B, "Peripheral T cell tolerance as a tumor escape mechanism : deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma", Eur. J. Immunol, 26, pp.2671~2679 (1996)
100. Staveley-O'Carroll K, "Induction of antigen-specific T cell anergy : An early event in the course of tumor progression", Proc. Natl. Acad. Sci. USA, 95, pp.1178~1183 (1998)
101. Vignali DA, "How regulatory T cells work", Nat. Rev. Immunol, 8, pp.523~532 (2008)
102. Sutmuller RP, "Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+)regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses", J. Exp. Med, 194, pp.823~832 (2001)
103. Ercolini AM, "Recruitment of latent pools of highavidity CD8(+)T cells to the antitumor immune response", J. Exp. Med, 201, pp.1591~1602 (2005)
104. Yu H, "STATs in cancer inflammation and immunity : a leading role for STAT3", Nat. Rev. Cancer, 9, pp.798~809 (2009)
105. Kusmartsev S, "Role of immature myeloid cells in mechanisms of immune evasion in cancer", Cancer Immunol. Immunother, 55, pp.237~245 (2006)
106. Young MR, "Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+)progenitor cells", Hum. Immunol, 62, pp.332~341 (2001)
107. Mazzoni A, "Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism", J. Immunol, 168, pp.689~695 (2002)
108. Nagaraj S, "Myeloid-derived suppressor cells in human cancer", Cancer J, 16, pp.348~353 (2010)
109. Gabrilovich DI, "Coordinated regulation of myeloid cells by tumours", Nat. Rev. Immunol, 12, pp.253~268 (2012)
110. Schmielau J, "Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients", Cancer Res, 61, pp.4756~4760 (2001)
111. Sears CL, "Microbes, microbiota, and colon cancer", Cell Host Microbe, 15, pp.317~328 (2014)
112. Yang Y, "Novel insights into microbiome in colitis and colorectal cancer", Curr. Opin. Gastroenterol, 33, pp.422~427 (2017)
113. Brennan CA, "Gut microbiota, inflammation, and colorectal cancer", Annu. Rev. Microbiol, 70, pp.395~411 (2016)
114. Nakatsu G, "Gut mucosal microbiome across stages of colorectal carcinogenesis", Nat. Commun, 6, pp.8727~ (2015)
115. Lu Y, "Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas", Sci. Rep, 6, pp.26337~ (2016)
116. Gao Z, "Microbiota disbiosis is associated with colorectal cancer", Front. Microbiol, 6, pp.20~ (2015)
117. Wong SH, "Gavage of fecal samples from patients with colorectal cancer promotes intestinal Carcinogenesis in Germ-Free and Conventional Mice", Gastroenterology, 153, pp.1621~1633 (2017)
118. Purcell RV, "Colonization with enterotoxigenic bacteroides fragilis is associated with early-stage colorectal neoplasia", PLoS One, 12, pp.e0171602~ (2017)
119. Wu S, "A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses", Nat. Med, 15, pp.1016~1022 (2009)
120. Boleij A, "The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients", Clin. Infect. Dis, 60, pp.208~215 (2015)
121. Mangerich A, "Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer", Proc. Natl. Acad. Sci. USA, 109, pp.1820~1829 (2012)
122. Gur C, "Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack", Immunity, 42, pp.344~355 (2015)
123. Dalmasso G, "The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment", Gut Microbes, 5, pp.675~680 (2014)
124. Tomkovich S, "Locoregional effects of microbiota in a preclinical model of colon carcinogenesis", Cancer Res, 77, pp.2620~2632 (2017)
125. He Z, "Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin", Gut, 68, pp.289~300 (2019)
126. Rubinstein MR, "Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin", beta-catenin signaling via its FadA adhesin, 2013, pp.14, 195~206
127. Mima K, "The microbiome and hepatobiliary-pancreatic cancers", Cancer Lett, 402, pp.9~15 (2017)
128. Yoshimoto S, "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", Nature, 499, pp.97~101 (2013)
129. Wang R, "Gut microbiome, liver immunology, and liver diseases", Cell Mol. Immunol, 18, pp.4~17 (2021)
130. Garcia-Castillo V, "Microbiota dysbiosis : a new piece in the understanding of the carcinogenesis puzzle", J. Med. Microbiol, 65, pp.1347~1362 (2016)
131. Kwa M, "The intestinal microbiome and estrogen receptor-positive female breast cancer", J. Natl. Cancer Inst. 10, 8, pp.djw029~ (2016)
132. Shapira I, "Evolving concepts : how diet and the intestinal microbiome act as modulators of breast malignancy", ISRN Oncol, 2013, pp.693920~ (2013)
133. Lakritz JR, "Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice", Int. J. Cancer, 135, pp.529~540 (2014)
134. Parhi L, "Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression", Nat. Commun, 11, pp.3259~ (2020)
135. Dong Q, "Host-microbiome interaction in lung cancer", Front. Immunol, 12, pp.679829~ (2021)
136. Weinberg F, "The lung microbiome : A central mediator of host inflammation and metabolism in lung cancer patients?", Cancers(Basel), 13, pp.13~ (2020)
137. Lloyd CM, "Lung homeostasis : influence of age, microbes, and the immune system", Immunity, 46, pp.549~561 (2017)
138. Palucka AK, "The basis of oncoimmunology", Cell, 164, pp.1233~1247 (2016)
139. Jin C, "Commensal microbiota promote lung cancer development via gammadelta T cells", Cell, 176, pp.998~1013 (2019)
140. Le Noci V, "Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy : a strategy to promote immunosurveillance against lung metastases", Cell Rep, 24, pp.3528~3538 (2018)
141. Segal LN, "Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype", Nat. Microbiol, 1, pp.16031~ (2016)
142. Postow MA, "Immune checkpoint blockade in cancer therapy", J. Clin. Oncol, 33, pp.1974~1982 (2015)
143. Frankel AE, "Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients", Neoplasia, 19, pp.848~855 (2017)
144. Routy B, "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors", Science, 359, pp.91~97 (2018)
145. Matson V, "The commensal microbiome is associated with anti-PD-1efficacy in metastatic melanoma patients", Science, 359, pp.104~108 (2018)
146. Gopalakrishnan V, "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
147. Sivan A, "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", Science, 350, pp.1084~1089 (2015)
148. Viaud S, "The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide", Science, 342, pp.971~976 (2013)
149. Iida N, "Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment", Science, 342, pp.967~970 (2013)
150. van Vliet MJ, "Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut", Clin. Infect. Dis, 49, pp.262~270 (2009)
151. Weber D, "Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome", Blood, 126, pp.1723~1728 (2015)
152. Jenq RR, "Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation", J. Exp. Med, 209, pp.903~911 (2012)
153. Jacobsohn DA, "Acute graft versus host disease", Orphanet. J. Rare Dis, 2, pp.35~ (2007)
154. Heimesaat MM, "MyD88", TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease, 2010, pp.59, 1079~1087
155. Dubin K, "Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis", Nat. Commun, 7, pp.10391~ (2016)
156. Wang F, "Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4blockade", Proc. Natl. Acad. Sci. USA, 115, pp.157~161 (2018)
157. Shen S, "Gut microbiota is critical for the induction of chemotherapy-induced pain", Nat. Neurosci, 20, pp.1213~1216 (2017)
158. Sokol H, "The microbiota : an underestimated actor in radiation-induced lesions?", Gut, 67, pp.1~2 (2018)
159. van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N. Engl. J. Med, 368, pp.407~415 (2013)
160. Bakken JS, "Treating Clostridium difficile infection with fecal microbiota transplantation", Clin. Gastroenterol. Hepatol, 9, pp.1044~1049 (2011)
161. Gostin LO, "Advancing the right to health-the vital role of law", Am. J. Public Health, 107, pp.1755~1756 (2017)
162. Shah MA, "Gastric cancer : The gastric microbiota-bacterial diversity and implications", Nat. Rev. Gastroenterol. Hepatol, 14, pp.692~693 (2017)
163. Doorakkers E, "Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population", Gut, 67, pp.2092~2096 (2018)
164. Choi IJ, "Helicobacter pylori Therapy for the prevention of metachronous gastric vancer", N. Engl. J. Med, 378, pp.1085~1095 (2018)
165. Zhou D, "Total fecal microbiota transplantation alleviates high-fat dietinduced steatohepatitis in mice via beneficial regulation of gut microbiota", Sci. Rep, 7, pp.1529~ (2017)
166. Ferrere G, "Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice", J. Hepatol, 66, pp.806~815 (2017)
167. Philips CA, "Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis : A pilot study", Clin. Gastroenterol. Hepatol, 15, pp.600~602 (2017)
168. Zhao L, "Gut bacteria selectively promoted by dietary fibers alleviate type 2diabetes", Science, 359, pp.1151~1156 (2018)
169. Trompette A, "Dietary fiber confers protection against flu by shaping Ly6c(-)patrolling monocyte hematopoiesis and CD8(+)T cell metabolism", Immunity, 48, pp.992~1005 (2018)
170. Wu GD, "Linking long-term dietary patterns with gut microbial enterotypes", Science, 334, pp.105~108 (2011)
171. Cotillard A, "Dietary intervention impact on gut microbial gene richness", Nature, 500, pp.585~588 (2013)
172. Sanders ME, "Probiotics and prebiotics in intestinal health and disease : from biology to the clinic", Nat. Rev. Gastroenterol. Hepatol, 16, pp.605~616 (2019)
173. Wang H, "Prebiotics : a potential treatment strategy for the chemotherapy-damaged gut?", Crit. Rev. Food Sci. Nutr, 56, pp.946~956 (2016)
174. Goldin BR, "Effect of Lactobacillus acidophilus dietary supplements on 1, 2-dimethylhydrazine dihydrochlorideinduced intestinal cancer in rats", J. Natl. Cancer Inst, 64, pp.263~265 (1980)
175. Thirabunyanon M, "Probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells", Biotechnol. Lett, 31, pp.571~576 (2009)
176. Dizman N, "Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma : a randomized phase 1 trial", Nat. Med, 28, pp.704~712 (2022)

관련 논문AI추천